|
|
|
|
LEADER |
01583nam a2200301 u 4500 |
001 |
EB001853591 |
003 |
EBX01000000000000001017894 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
181108 r ||| eng |
100 |
1 |
|
|a Kim, Joanne
|
245 |
0 |
0 |
|a Ketamine for treatment-resistant depression or post-traumatic stress disorder in various settings
|h Elektronische Ressource
|b a review of clinical effectiveness, safety, and guidelines
|c Joanne Kim, Monika Mierzwinski-Urban
|
260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2017, March 1, 2017
|
300 |
|
|
|a 1 PDF file (30 pages)
|b illustrations
|
505 |
0 |
|
|a Includes bibliographical references
|
653 |
|
|
|a Ketamine / therapeutic use
|
653 |
|
|
|a Stress Disorders, Post-Traumatic / drug therapy
|
653 |
|
|
|a Off-Label Use
|
653 |
|
|
|a Treatment Outcome
|
653 |
|
|
|a Depressive Disorder, Treatment-Resistant / drug therapy
|
700 |
1 |
|
|a Mierzwinski-Urban, Monika
|e [author]
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a Rapid response report: summary with critical appraisal
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK487457
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
082 |
0 |
|
|a 610
|
520 |
|
|
|a To inform clinical practice on the treatment of patients with TRD or PTSD, this report aimed to provide evidence on the clinical benefits and harms and evidence-based guidelines on the off-label use of ketamine in various settings
|